1981PubMedRequires access

[Interactions of phenylbutazone and oxyphenbutazone with glymidine (author's transl)].

Michael E. Held, G Scheible

Open publisher page 1 citations

Abstract

In healthy subjects plasma concentrations of 2-benzenesulfonylamino-4-(beta-methoxy-ethoxy)pyrimidine (glymidine) are considerably elevated during ingestion of 600 mg oxyphenbutazone additionally to 500 mg glymidine per day. In contrast phenylbutazone has only a slight and not significant effect on the glymidine plasma concentrations. In vitro equilibrium dialysis experiments show a decrease of serum protein binding of glymidine after the addition of phenylbutazone and oxyphenbutazone. The increase of the glymidine plasma concentrations together with the decrease of serum protein binding is predestined to lead to an increased pharmacodynamic effect of the drug.

About this research paper

What this paper is about

In healthy subjects plasma concentrations of 2-benzenesulfonylamino-4-(beta-methoxy-ethoxy)pyrimidine (glymidine) are considerably elevated during ingestion of 600 mg oxyphenbutazone additionally to 500 mg glymidine per day. In contrast phenylbutazone has only a slight and not significant effect on the glymidine plasma concentrations. In vitro equilibrium dialysis experiments show a decrease of serum protein binding of glymidine after the addition of phenylbutazone and oxyphenbutazone. The increase of the glymidine plasma concentrations together with the decrease of serum protein binding is predestined to lead to an increased pharmacodynamic effect of the drug.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

In healthy subjects plasma concentrations of 2-benzenesulfonylamino-4-(beta-methoxy-ethoxy)pyrimidine (glymidine) are considerably elevated during ingestion of 600 mg oxyphenbutazone additionally to 500 mg glymidine per day. In contrast phenylbutazone has only a slight and not significant effect on the glymidine plasma concentrations. In vitro equilibrium dialysis experiments show a decrease of serum protein binding of glymidine after the addition of phenylbutazone and oxyphenbutazone. The increase of the glymidine plasma concentrations together with the decrease of serum protein binding is predestined to lead to an increased pharmacodynamic effect of the drug.

Key concepts: Oxyphenbutazone, Phenylbutazone, Chemistry, Pharmacology, Plasma levels, Blood proteins, Medicine, Internal medicine

Related papers

Back to paper searchBrowse research topicsOriginal source
[Interactions of phenylbutazone and oxyphenbutazone with glymidine (author's transl)]. — Research Paper | ScholarLens